GlassScriptPhysician profile
Claire Wolinsky-Berkowitz
NPI 1043535511
$62,271.29
in general payments reported to CMS, 2019-2025
29 companies · $54K in 2025
The $54K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $510 · 2021: $653 · 2022: $587 · 2023: $5,012 · 2024: $445 · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $1,709 · Travel and Lodging: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,500.00 |
| Food and Beverage | $1,709.33 |
| Travel and Lodging | $241.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $59,093.28 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $966.86 | 2019-2022 | |
| Abbvie INC. | $263.12 | 2019-2025 | Skyrizi |
| Pfizer INC. | $248.62 | 2019-2023 | |
| Incyte Corporation | $210.10 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $187.71 | 2019-2021 | |
| Allergan, INC. | $171.77 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.37 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Botanix Sb INC | $113.17 | 2025 | Sofdra |
| Amgen INC. | $107.19 | 2020-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2020-2025 | Dupixent |
| Dermavant Sciences, INC. | $97.19 | 2022-2024 | Vtama |
| Genzyme Corporation | $87.92 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $81.54 | 2024-2025 | |
| Medimetriks Pharmaceuticals, INC. | $52.48 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $49.36 | 2024 | Adbry |
| Vyne Pharmaceuticals INC. | $39.74 | 2020 | |
| Sun Pharmaceutical Industries INC. | $33.88 | 2023 | Absorica Ld, Winlevi |
| Verrica Pharmaceuticals INC. | $32.30 | 2025 | Ycanth |
| Celgene Corporation | $24.21 | 2019 | |
| Janssen Biotech, INC. | $23.37 | 2025 | Tremfya |
| Lilly USA, LLC | $22.38 | 2022 | |
| Glaxosmithkline, LLC. | $22.04 | 2024 | Bexsero, Pediarix |
| Journey Medical Corporation | $21.22 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.10 | 2020 | |
| Epi Health, LLC | $17.23 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2024 | Sotyktu |
| Mylan Pharmaceuticals INC. | $14.78 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Wolinsky-Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.